In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product sales. However, it expects its combined collaboration revenue and core other operating income and expenses to fall YoY (year-over-year), and has guided for a low single-digit percentage revenue impact by foreign exchange.
Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
Analysts expect AstraZeneca’s revenue to rise 5.84% YoY to $23.38 billion in fiscal 2019, 12.36% YoY to $26.27 billion in fiscal 2020, and 13.48% YoY to $29.81 billion in fiscal 2021. They expect AstraZeneca’s revenue to rise 8.18% YoY to $5.58 billion in the second quarter of fiscal 2019, 10.96% YoY to $5.93 billion in the third quarter, and 1.07% YoY to $6.49 billion in the fourth quarter.
In the first quarter, AstraZeneca’s oncology sales rose 54% YoY to $1.89 billion on a reported basis and 59% on a CER basis. Its new cardiovascular, renal, and metabolism product sales rose 15% YoY to $1.03 billion on a reported basis and 19% on a CER basis, and its respiratory product sales rose 9% YoY to $1.28 billion on a reported basis and 14% on a CER basis.
AstraZeneca’s emerging market sales, which accounted for ~37% of the company’s total sales in the first quarter, rose 14% YoY to $2.00 billion on a reported basis and 22% on a CER basis. Of these, China was the largest revenue contributor and accounted for $1.24 billion in revenue, marking a 21% rise YoY on a reported basis and 28% on a CER basis. The company’s sales from ex-China markets rose 3% YoY to $762 million on a reported basis and 13% on a CER basis.